
Yuji Uehara/X
Mar 3, 2025, 11:31
Yuji Uehara: Morning immuno-chemotherapy nearly doubled survival in NSCLC
Yuji Uehara, Medical Oncologist at National Cancer Center Japan, shared a post on X about a paper by Zhe Huang et al. published in eBioMedicine:
“Timing might matter in NSCLC! A bi-continental study shows morning immuno-chemotherapy (before 11:30 AM) nearly doubled survival vs afternoon dosing (33.0 vs 19.5 months). RWE from France and China – time to rethink the schedule of immunotherapy!”
Authors: Zhe Huang, Abdoulaye Karaboué, Liang Zeng, Yongchang Zhang, Francis Lévi et al.
More posts featuring Yuji Uehara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37